Who Owns Eurobio Scientific Company?

Eurobio Scientific Bundle

Get Full Bundle:

	SWOT	$15	$10
	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10

TOTAL:

ADD TO CART

Who Truly Controls Eurobio Scientific?

Understanding the ownership of a company is paramount for any investor or strategist. A company's strategic direction, governance, and overall market influence are deeply intertwined with its ownership structure. Eurobio Scientific, a prominent player in in vitro medical diagnostics, recently experienced a significant transformation in its ownership landscape. This article unveils the intricacies of Eurobio Scientific SWOT Analysis, exploring the evolution of its ownership from its founding to the present day.

This deep dive into Eurobio Scientific will explore the roles of its founders, key investors, and public shareholders, providing crucial insights for anyone seeking to understand the Eurobio Scientific ownership dynamics. We'll examine the impact of recent developments on the Eurobio Scientific company, including its financial performance, with a reported revenue of €154.2 million as of December 31, 2024. Discover the answers to questions like "Who owns Eurobio?" and "Who are the major Eurobio Scientific shareholders?" to gain a comprehensive understanding of this dynamic organization.

The founders and early ownership structure of the Eurobio Scientific company are key to understanding its development. While specific details about the initial equity split at the company's inception in 1998 are not readily available in public records, key individuals have played crucial roles in shaping the company. The current leadership structure and significant shareholder involvement offer insights into the company's ownership and strategic direction.

Jean-Michel Carle and Denis Fortier are notable as directors within the Eurobio Scientific company, particularly through their connection to the EurobioNext holding company, which acts as a reference shareholder. Denis Fortier currently holds the positions of Chairman and Chief Executive Officer. Jean-Michel Carle-Grandmougin is also a Director and Deputy Executive Officer. These individuals, along with other board members and senior management, have maintained a substantial stake in the company. This continued involvement reflects a long-term commitment to the company's vision.

Information regarding early backers and angel investors is not extensively detailed in publicly available sources. However, the ongoing involvement of the founders in the ownership structure, especially through EurobioNext, suggests a sustained dedication to the company's goals. There is no readily accessible public information on initial ownership disputes, buyouts, or specific early agreements. The founding team's vision for Eurobio Scientific, focusing on in vitro diagnostics and life science products, has been consistently pursued through strategic developments and acquisitions, highlighting their continued influence and direction.

Key Figures

Denis Fortier: Chairman and CEO

Jean-Michel Carle-Grandmougin: Director and Deputy Executive Officer

EurobioNext: Reference shareholder

Ownership Structure

Founders maintain significant stakes.

No public details on early investors or disputes.

Focus on long-term strategic goals.

Strategic Direction

Emphasis on in vitro diagnostics and life science products.

Strategic developments and acquisitions.

Sustained control and vision from the founding team.

Company History

Founded in 1998.

Focus on strategic growth.

Continuous adaptation to market demands.

Shareholder Commitment

Long-term vision.

Continued investment.

Strategic planning.

Public Information

Limited details on early ownership.

Focus on current leadership.

Information from public sources.

Ownership Insights

Understanding the Eurobio Scientific ownership structure is crucial for investors and stakeholders. The consistent presence of founders and key executives, particularly through the EurobioNext holding, highlights a commitment to the company's long-term vision. While specific details on early Eurobio Scientific shareholders and initial investments are not widely available, the current leadership's influence underscores their dedication to the company's strategic direction. For more details on the company's strategic approach, consider reading about the Growth Strategy of Eurobio Scientific.

• Key individuals like Denis Fortier and Jean-Michel Carle-Grandmougin play pivotal roles.
• EurobioNext serves as a significant reference shareholder.
• The focus remains on in vitro diagnostics and life science products.
• Strategic acquisitions and developments are key to the company's growth.

Eurobio Scientific SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

The ownership of Eurobio Scientific has seen considerable changes since its Initial Public Offering (IPO) on Euronext Growth Paris on November 17, 2005. The company's share capital, as of December 31, 2024, comprised 10,248,871 shares, each with a nominal value of €0.32.

A significant shift occurred with the tender offer initiated by EB Development. As of December 19, 2024, EB Development, in collaboration with funds managed by NextStage AM and IK Partners, including Denis Fortier (Chairman and CEO) and other board members and senior management, held 9,113,592 shares, representing 88.92% of Eurobio Scientific's share capital and voting rights. This stake further increased to 9,224,652 shares, or 90.01% of the share capital and voting rights, as of May 19, 2025, through market acquisitions.

This concentrated ownership, spearheaded by EB Development, which includes directors Jean-Michel Carle and Denis Fortier, along with investments from AXA, NextStage AM, and IK Partners, reflects a strategic shift. The consortium's aim was to provide Eurobio Scientific with a new institutional partner to boost its growth, potentially establishing it as a market leader. This move towards private ownership, backed by private equity firms, is designed to support long-term development, moving away from the limitations of public listing. For further information on the company, you can explore a comprehensive [Eurobio Scientific company profile].

Key Takeaways on Eurobio Scientific Ownership

The ownership structure of Eurobio Scientific has evolved significantly, particularly with the recent tender offer. EB Development, in partnership with NextStage AM and IK Partners, now holds a dominant stake.

• EB Development's ownership reached 90.01% by May 19, 2025.
• The shift aims to foster long-term growth away from public market constraints.
• The company's leadership and key investors are now primarily focused on private market strategies.

Eurobio Scientific PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

The Board of Directors of the Eurobio Scientific company is central to its governance, shaped by a concentrated ownership structure. The board, which can have between three and eighteen members, serves three-year terms that are renewable. This structure ensures a focused approach to strategic decisions and oversight.

The current board includes key figures such as Denis Fortier, Chairman and CEO, who also has a direct stake in EB Development. Jean-Michel Carle Grandmougin and Hervé Duchesne de Lamotte serve as Directors and Deputy Executive Officers. Other board members include Grégoire Sentilhes representing EurobioNext SAS, Michel Picot, and Patrick de Roquemaurel. This composition reflects a blend of leadership and shareholder representation, guiding the company's direction.

The voting power within Eurobio Scientific ownership is significantly influenced by EB Development, which holds 90.01% of both the share capital and voting rights. This structure, which includes major Eurobio Scientific investors like NextStage AM and IK Partners, gives EB Development substantial control over the company's strategic decisions. The board operates on a majority vote basis, provided at least half the members are present. This governance model highlights a unified approach to the company's expansion and market positioning.

Key Takeaways on Eurobio Scientific Ownership

The board's composition and the concentrated ownership structure of Eurobio Scientific are critical to understanding its governance. EB Development's significant stake gives it considerable influence. The board's structure ensures focused decision-making.

• EB Development controls a large majority of voting rights.
• The board includes key executives and shareholder representatives.
• Decisions are made by majority vote, with a quorum requirement.
• The current structure supports a unified strategic direction.

Eurobio Scientific Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Over the past few years, the ownership landscape of Eurobio Scientific has undergone significant changes. A strategic tender offer and subsequent acquisitions have reshaped the company's shareholder structure. In December 2024, EB Development, a consortium including funds managed by NextStage AM and IK Partners, alongside Eurobio Scientific's key leadership, completed a tender offer. This resulted in them holding 88.92% of the company's shares and voting rights.

This controlling stake further increased to 90.01% by May 19, 2025, through additional market acquisitions. This move was designed to support the company's growth, backed by active shareholders. This strategic shift towards a more concentrated ownership aligns with the goal of fostering faster organic and inorganic growth for the Eurobio Scientific company.

Eurobio Scientific has been actively pursuing mergers and acquisitions to bolster its market position. The company acquired Alpha Biotech in January 2024. Furthermore, in August 2024, the acquisition of the EndoPredict® and Prolaris® oncology businesses from Myriad Genetics was completed, generating €3.8 million in sales in 2024. More recently, in March 2025, Eurobio Scientific finalized the acquisition of Quimark SRL, a distributor of its oncology products in Italy, and signed an agreement in March 2025 to acquire the assets of the Life Science unit of Voden Medical Instruments Spa, with completion expected by July 1, 2025. These Italian acquisitions are anticipated to contribute approximately €10 million in new revenues annually. If you would like to learn more about the company, you can read the Brief History of Eurobio Scientific.

Ownership Structure

The ownership is now primarily controlled by a consortium including NextStage AM, IK Partners, and key management, reflecting a strategic shift.

Key Acquisitions

Recent acquisitions include Alpha Biotech, the oncology businesses from Myriad Genetics, and Quimark SRL, expanding market reach and product offerings.

Strategic Goals

The company aims for significant growth in sales and margins, with a medium-term goal of proprietary products accounting for around 50% of revenues.

Upcoming Event

The Annual General Meeting is scheduled for June 19, 2025, which will provide further insights into the company's future plans.

Eurobio Scientific Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔

Related Blogs